Follow Us
© 2026 Arizent. All rights reserved.
Psst! PBMs don’t want you to know about a class-action settlement involving prescription medicine pricing could result in drug-spend savings of 0.7% to 1.6% for plan sponsors. (Every penny helps these days, right?)
In a March EBN cover story, contributors Emil Kraft and Scott Rogers advice benefit managers about how some pharmacy benefit managers are attempting to reduce or eliminate the savings from the suit by changing pharmacy contracts. Don’t lost out: Read the story here.
For reprint and licensing requests for this article, click here.
Much has been written recently about the increased scrutiny of employer's fiduciary responsibility related to the health and welfare plans offered to their employees.
Hello, DD followers. I know I didn't live up to the 'Daily' in our title last week, and for that I sincerely apologize. To say the last several weeks have been a challenge would be a huge understatement, but I'm ready to make good, and have what I think is a great peace offering — a first look at EBN's August podcasts! Not yet promoted on the rest of the site, in the magazine or
On March 30, a District Court in Massachusetts made a final judgment to approve a class-action setlement involving First Databank and Medi-Span, two major publishers of drug pricing information.